{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:31:31Z","timestamp":1793309491838,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.chest.2026.09.016","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:18:16Z","timestamp":1790003896000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in Inhaled Antibiotic-Associated Lung Function Outcomes in the CFTR Modulator Era"],"prefix":"10.1016","author":[{"given":"Marianne S.","family":"Muhlebach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"LiPuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Kosorok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.chest.2026.09.016_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.2009","article-title":"Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition","volume":"32","author":"Kosorok","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.chest.2026.09.016_bib2","unstructured":"Cystic Fibrosis Foundation Patient Registry. Accessed January 2019."},{"issue":"10","key":"10.1016\/j.chest.2026.09.016_bib3","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.chest.2026.09.016_bib4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2026.09.016_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.chest.2026.09.016_bib6","doi-asserted-by":"crossref","unstructured":"Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol. 45(11):1121-1134.","DOI":"10.1002\/ppul.21301"},{"issue":"1","key":"10.1016\/j.chest.2026.09.016_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcf.2024.09.017","article-title":"Changes in factors associated with inhaled antibiotic prescriptions for people with cystic fibrosis over time in the U.S","volume":"24","author":"Muhlebach","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.chest.2026.09.016_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.chest.2026.09.016_bib9","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.chest.2026.09.016_bib10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2023.02.009","article-title":"Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020","volume":"22","author":"Cromwell","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.chest.2026.09.016_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.chest.2026.09.016_bib12","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2026.09.016_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01241-2023","article-title":"Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain","volume":"63","author":"Kerem","year":"2024","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2026.09.016_bib14","first-page":"CD001021","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis","volume":"3","author":"Smith","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.chest.2026.09.016_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1440-1681.12086","article-title":"Should we use one-sided or two-sided P values in tests of significance?","volume":"40","author":"Ludbrook","year":"2013","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4","key":"10.1016\/j.chest.2026.09.016_bib16","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"issue":"1","key":"10.1016\/j.chest.2026.09.016_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2022.08.010","article-title":"Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection - a European cystic fibrosis patient registry data analysis","volume":"22","author":"Orenti","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.chest.2026.09.016_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.04.007","article-title":"Association between inhaled antibiotic use and treatment-emergent organisms among Canadian people with cystic fibrosis","author":"Cogen","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"suppl 1","key":"10.1016\/j.chest.2026.09.016_bib19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/676882","article-title":"Infection prevention and control guideline for cystic fibrosis: 2013 update","volume":"35","author":"Saiman","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"10.1016\/j.chest.2026.09.016_bib20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/ppul.22874","article-title":"Clinical use of tobramycin inhalation solution (TOBI\u00ae) shows sustained improvement in FEV1 in cystic fibrosis","volume":"49","author":"Konstan","year":"2014","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.chest.2026.09.016_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1513\/AnnalsATS.201209-082OC","article-title":"Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis","volume":"10","author":"VanDyke","year":"2013","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.chest.2026.09.016_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jcf.2024.10.006","article-title":"Factors associated with prescription of elexacaftor\/tezacaftor\/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele","volume":"24","author":"Hergenroeder","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.chest.2026.09.016_bib23","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jcf.2018.01.008","article-title":"Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis","volume":"17","author":"Hong","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.chest.2026.09.016_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75886-w","article-title":"Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function","volume":"10","author":"Duesberg","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.chest.2026.09.016_bib25","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1164\/rccm.201908-1585OC","article-title":"Aspergillus infections and progression of structural lung disease in children with cystic fibrosis","volume":"201","author":"Breuer","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.chest.2026.09.016_bib26","article-title":"The effects of Aspergillus fumigatus colonization on lung function in patients with cystic fibrosis","volume":"7","author":"Al Shakirchi","year":"2021","journal-title":"J Fungi (Basel)"},{"issue":"7","key":"10.1016\/j.chest.2026.09.016_bib27","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1513\/AnnalsATS.202210-852OC","article-title":"The clinical association between Aspergillus fumigatus and respiratory outcomes in adolescents and adults with cystic fibrosis","volume":"20","author":"O'Dea","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.chest.2026.09.016_bib28","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1378\/chest.121.6.1754","article-title":"Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis","volume":"121","author":"Graff","year":"2002","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.chest.2026.09.016_bib29","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s10096-023-04648-z","article-title":"Stenotrophomonas maltophilia in people with cystic fibrosis: a systematic review of prevalence, risk factors and management","volume":"42","author":"Terlizzi","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.chest.2026.09.016_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108464","article-title":"Discontinuation of supportive therapies in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor - a patient-reported outcomes' study","volume":"249","author":"Ahting","year":"2025","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.chest.2026.09.016_bib31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2025.11.016","article-title":"Elexacaftor\/tezacaftor\/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis","volume":"25","author":"Sagel","year":"2026","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.chest.2026.09.016_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2025.08.012","article-title":"Change in pulmonary pathogens 3 years after elexacaftor\/tezacaftor\/ivacaftor: an observational study in the Danish cystic fibrosis cohort","author":"Bendixen","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.chest.2026.09.016_bib34","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s42003-024-06618-3","article-title":"RNA-Seq reveals that Pseudomonas aeruginosa mounts growth medium-dependent competitive responses when sensing diffusible cues from Burkholderia cenocepacia","volume":"7","author":"Leinweber","year":"2024","journal-title":"Commun Biol"},{"issue":"11","key":"10.1016\/j.chest.2026.09.016_bib35","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1128\/IAI.01876-14","article-title":"Localization of Burkholderia cepacia complex bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa in hypoxic mucus","volume":"82","author":"Schwab","year":"2014","journal-title":"Infect Immun"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226066754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226066754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:51:38Z","timestamp":1793307098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369226066754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"alternative-id":["S0012369226066754"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2026.09.016","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in Inhaled Antibiotic-Associated Lung Function Outcomes in the CFTR Modulator Era","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2026.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}